Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? DOI Creative Commons
Mara Serena Serafini, Elisabetta Molteni, Eleonora Nicolò

et al.

The Journal of Liquid Biopsy, Journal Year: 2023, Volume and Issue: 3, P. 100132 - 100132

Published: Dec. 12, 2023

Despite a significant evolution in treatment strategies for early breast cancer (EBC) patients, up to 30% of them experience recurrence due occult micrometastasis. The minimal residual disease (minimal RD) EBC patients after the with curative intent cannot be easily detected by clinical examination and radiological imaging, as they are both burdened limited sensitivity. A new frontier promising approach address this unmet need is study liquid biopsy (LB). most studied tumor-derived analytes peripheral blood RD monitoring currently: i) circulating tumor DNA (ctDNA), detection somatic alterations, so referred molecular (MRD); ii) cells (CTCs), cellular (CRD). MRD detection, while reaching high specificity, still presenting number limitations. On other hand, CRD allows real-time monitoring, detecting live cells, possess potential provide an enormous amount biological information. Indeed, CTCs can multi-level portrait (i.e., DNA, RNA proteins) tumor, longitudinally depicting its evolving landscape, used functional (in vitro/in vivo) characterization. Moreover, goes beyond association risk recurrence: predictive biomarkers response also evaluated. Nevertheless, less context, because their immediately processed small fraction post-surgery setting. These limitations could however overcome use newly developed technologies that enable increased CTC rate retrospective studies. Here, we review strengths using focusing on methodologies available LB analysis setting, main studies investigating EBC. Considering limits advantages CRD, propose integration ctDNA complementary tools assessment achieve synergistic novel analysis.

Language: Английский

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy DOI Creative Commons
Matin Chehelgerdi,

Fereshteh Behdarvand Dehkordi,

Mohammad Chehelgerdi

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: Nov. 28, 2023

The advent of iPSCs has brought about a significant transformation in stem cell research, opening up promising avenues for advancing cancer treatment. formation is multifaceted process influenced by genetic, epigenetic, and environmental factors. offer distinctive platform investigating the origin cancer, paving way novel approaches to treatment, drug testing, tailored medical interventions. This review article will provide an overview science behind iPSCs, current limitations challenges iPSC-based therapy, ethical social implications, comparative analysis with other types also discuss applications tumorigenesis, future tumorigenesis highlight successful case studies utilizing research. conclusion summarize advancements made research importance continued investment iPSC unlock full potential these cells.

Language: Английский

Citations

75

Beyond Extracellular Vesicles: Hybrid Membrane Nanovesicles as Emerging Advanced Tools for Biomedical Applications DOI Creative Commons
Meng Sun,

Jiani Yang,

Yueyun Fan

et al.

Advanced Science, Journal Year: 2023, Volume and Issue: 10(32)

Published: Sept. 25, 2023

Extracellular vesicles (EVs), involved in essential physiological and pathological processes of the organism, have emerged as powerful tools for disease treatment owing to their unique natural biological characteristics artificially acquired advantages. However, limited targeting ability, insufficient production yield, low drug-loading capability simplex EVs greatly hindered development clinical translation. Therefore, establishment multifunctional hybrid membrane nanovesicles (HMNVs) with favorable adaptability flexibility has become key expanding practical application EVs. This timely review summarizes current progress HMNVs biomedical applications. Different preparation strategies including physical, chemical, chimera approaches are first discussed. then individually describes diverse types based on homologous or heterologous cell substances, a fusion liposome, well bacterial membrane. Subsequently, specific emphasis is placed highlight applications toward various diseases representative examples. Finally, ongoing challenges prospects currently developed translational briefly presented. will not only stimulate broad interest among researchers from disciplines but also provide valuable insights promising nanoplatforms precision medicine.

Language: Английский

Citations

46

Pancreatic cancer environment: from patient-derived models to single-cell omics DOI

Ao Gu,

Jiatong Li,

Shimei Qiu

et al.

Molecular Omics, Journal Year: 2024, Volume and Issue: 20(4), P. 220 - 233

Published: Jan. 1, 2024

This review initially presents relevant patient-derived models, including PDXs, PDOs, and PDEs. Subsequently, a comprehensive summary of single-cell analyses conducted on these models is provided.

Language: Английский

Citations

26

The role of extracellular vesicles in circulating tumor cell-mediated distant metastasis DOI Creative Commons

Siyin Guo,

Jing Huang, Genpeng Li

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: Nov. 30, 2023

Current research has demonstrated that extracellular vesicles (EVs) and circulating tumor cells (CTCs) are very closely related in the process of distant metastasis. Primary tumors shed released into bloodstream to form CTCs referred as seeds colonize grow soil-like target organs, while EVs nontumor origin act fertilizers There is no previous text provides a comprehensive review role on during In this paper, we reviewed mechanisms metastasis, including ability enhance shedding CTCs, protect circulation determine direction CTC thus affecting metastasis tumors.

Language: Английский

Citations

31

Development of antibody‐drug conjugates in cancer: Overview and prospects DOI Creative Commons

Dan‐Yun Ruan,

Hao‐Xiang Wu,

Qi Meng

et al.

Cancer Communications, Journal Year: 2023, Volume and Issue: 44(1), P. 3 - 22

Published: Dec. 30, 2023

Abstract In recent years, remarkable breakthroughs have been reported on antibody‐drug conjugates (ADCs), with 15 ADCs successfully entering the market over past decade. This substantial development has positioned as one of fastest‐growing domains in realm anticancer drugs, demonstrating their efficacy treating a wide array malignancies. Nonetheless, there is still an unmet clinical need for wider application, better efficacy, and fewer side effects ADCs. An ADC generally comprises antibody, linker payload, combination profound drug structure, pharmacokinetic profile efficacy. Hence, optimization key components provides opportunity to develop higher potency effects. this review, we comprehensively reviewed current prospects ADC, provided analysis marketed ongoing pipelines globally well China, highlighted several platforms technologies specific different pharmaceutical enterprises biotech companies, also discussed new related technologies, possibility next‐generation directions research.

Language: Английский

Citations

30

The role of organoids in cancer research DOI Creative Commons
Zhen Fang, Peijuan Li, Fengying Du

et al.

Experimental Hematology and Oncology, Journal Year: 2023, Volume and Issue: 12(1)

Published: Aug. 3, 2023

Organoids are established through in vitro 3D culture, and they can mimic the structure physiological functions of organs or tissues vivo. have attracted much attention recent years. They provide a reliable technology platform for cancer research treatment valuable preclinical model academic personalized medicine. A number studies confirmed that organoids great application prospects new drug development, screening, tumour mechanism research, precision In this review, we mainly focus on advances research. We also discussed opportunities challenges facing organoids, hoping to indicate directions development future.

Language: Английский

Citations

26

Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy DOI
Binglei Zhang, Jianxiang Shi, Xiaojing Shi

et al.

Drug Resistance Updates, Journal Year: 2024, Volume and Issue: 74, P. 101068 - 101068

Published: Feb. 13, 2024

Language: Английский

Citations

18

The omics technologies and liquid biopsies: Advantages, limitations, applications DOI Creative Commons
Daniele Magro,

Marika Venezia,

Carmela Rita Balistreri

et al.

Medicine in Omics, Journal Year: 2024, Volume and Issue: 11, P. 100039 - 100039

Published: May 21, 2024

Over the last few years, development of so-called omics technologies has greatly contributed to discovery new biomarkers and targets, embracing various fields from diagnostics therapy contributing meliorate advance precision personalized medicine. In addition classic omics, including genomics, transcriptomics, proteomics, metabolomics, newer-generation their platforms, such as microbiomics nutrigenomics, are emerging. parallel, use liquid biopsies, optimal biological samples, consisting in fluids (i.e. blood, saliva, urine) easy collect, whose components (cells, nucleic acids, exosome) can be analysed using throughput techniques, is becoming an attractive, because enables extrapolation big data via multi-omics technologies. Here, we report a brief description discussion technologies, by evidencing applications eventual limitations.

Language: Английский

Citations

14

Exosomes: from basic research to clinical diagnostic and therapeutic applications in cancer DOI Creative Commons
Salomé Araujo‐Abad, José Berná,

Elena Lloret-Lopez

et al.

Cellular Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 19, 2024

Language: Английский

Citations

12

Machine learning-based analysis identifies and validates serum exosomal proteomic signatures for the diagnosis of colorectal cancer DOI Creative Commons
Haofan Yin, Jinye Xie, Shan Xing

et al.

Cell Reports Medicine, Journal Year: 2024, Volume and Issue: 5(8), P. 101689 - 101689

Published: Aug. 1, 2024

Language: Английский

Citations

10